TN2015000128A1 - Solid form of dihydro-pyrido-oxazine derivative - Google Patents

Solid form of dihydro-pyrido-oxazine derivative

Info

Publication number
TN2015000128A1
TN2015000128A1 TNP2015000128A TN2015000128A TN2015000128A1 TN 2015000128 A1 TN2015000128 A1 TN 2015000128A1 TN P2015000128 A TNP2015000128 A TN P2015000128A TN 2015000128 A TN2015000128 A TN 2015000128A TN 2015000128 A1 TN2015000128 A1 TN 2015000128A1
Authority
TN
Tunisia
Prior art keywords
pyrido
dihydro
solid form
oxazine derivative
forms
Prior art date
Application number
TNP2015000128A
Other languages
English (en)
Inventor
Konstanze Hurth
Christoph Kalis
Karen Kammertoens
Nicolas Soldermann
Frédéric Zecri
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51019963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000128(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2015000128A1 publication Critical patent/TN2015000128A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2015000128A 2012-11-26 2015-04-02 Solid form of dihydro-pyrido-oxazine derivative TN2015000128A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GC201222895 2012-11-26
IR1391307213 2012-12-04
PCT/IB2013/060412 WO2014102630A1 (fr) 2012-11-26 2013-11-26 Forme solide d'un dérivé de dihydro-pyrido-oxazine

Publications (1)

Publication Number Publication Date
TN2015000128A1 true TN2015000128A1 (en) 2016-10-03

Family

ID=51019963

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000128A TN2015000128A1 (en) 2012-11-26 2015-04-02 Solid form of dihydro-pyrido-oxazine derivative

Country Status (23)

Country Link
EP (1) EP2928896B1 (fr)
KR (1) KR102184069B1 (fr)
CN (1) CN104870451B (fr)
AU (1) AU2013368997B8 (fr)
BR (1) BR112015009870A2 (fr)
CA (1) CA2891521A1 (fr)
CL (1) CL2015001409A1 (fr)
CY (1) CY1119702T1 (fr)
DK (1) DK2928896T3 (fr)
GT (1) GT201500124A (fr)
HK (1) HK1209419A1 (fr)
IL (1) IL238889B (fr)
MX (1) MX366342B (fr)
NZ (1) NZ706865A (fr)
PE (1) PE20150946A1 (fr)
PH (1) PH12015501052A1 (fr)
PL (1) PL2928896T3 (fr)
PT (1) PT2928896T (fr)
SG (1) SG11201503410VA (fr)
TN (1) TN2015000128A1 (fr)
TW (1) TW201422625A (fr)
WO (1) WO2014102630A1 (fr)
ZA (1) ZA201502350B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200286A (es) 2011-12-22 2020-09-23 Novartis Ag DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MA53219A (fr) 2018-08-13 2021-11-17 Hoffmann La Roche Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MX2022002311A (es) 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
CA2216796C (fr) 1995-03-30 2003-09-02 Pfizer Inc. Derives de quinazoline
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
SK398A3 (en) 1995-07-06 1998-07-08 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
CA2258548C (fr) 1996-06-24 2005-07-26 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
EP0923583A1 (fr) 1996-08-30 1999-06-23 Novartis AG Procede de fabrication d'epothilones, et composes intermediaires obtenus au cours de ce procede
WO1998010121A1 (fr) 1996-09-06 1998-03-12 Obducat Ab Procede de gravure anisotrope de structures dans des materiaux conducteurs
EP0954315A2 (fr) 1996-09-13 1999-11-10 Sugen, Inc. Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
PE20020544A1 (es) 2000-11-07 2002-07-30 Novartis Ag Derivados de indolilmaleimida
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
BR0317099A (pt) 2002-12-09 2005-10-25 Boardd Of Regents Of The Unive Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
UA96736C2 (ru) * 2005-09-07 2011-12-12 Мерк Сероно Са Ингибиторы pi3k для лечения эндометриоза
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
CR20200286A (es) * 2011-12-22 2020-09-23 Novartis Ag DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)

Also Published As

Publication number Publication date
ZA201502350B (en) 2017-08-30
HK1209419A1 (en) 2016-04-01
GT201500124A (es) 2016-03-01
CA2891521A1 (fr) 2014-07-03
MX2015006650A (es) 2015-08-10
CL2015001409A1 (es) 2015-07-24
AU2013368997A1 (en) 2015-04-30
PE20150946A1 (es) 2015-06-28
IL238889B (en) 2021-03-25
EP2928896B1 (fr) 2017-07-19
EP2928896A1 (fr) 2015-10-14
CY1119702T1 (el) 2018-06-27
PL2928896T3 (pl) 2018-01-31
PT2928896T (pt) 2017-10-25
AU2013368997B2 (en) 2015-09-24
WO2014102630A1 (fr) 2014-07-03
DK2928896T3 (da) 2017-11-06
IL238889A0 (en) 2015-07-30
AU2013368997B8 (en) 2015-10-08
CN104870451B (zh) 2017-07-07
PH12015501052A1 (en) 2015-07-27
SG11201503410VA (en) 2015-05-28
TW201422625A (zh) 2014-06-16
NZ706865A (en) 2016-04-29
BR112015009870A2 (pt) 2017-12-05
CN104870451A (zh) 2015-08-26
AU2013368997A8 (en) 2015-10-08
KR20150091047A (ko) 2015-08-07
MX366342B (es) 2019-07-05
KR102184069B1 (ko) 2020-11-30

Similar Documents

Publication Publication Date Title
MY192259A (en) Aryl and heteroaryl fused lactams
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
EA201200486A1 (ru) Лечение онкологических заболеваний
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
IN2014CN03597A (fr)
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
PH12013501321A1 (en) Phenoxymethyl heterocyclic compounds
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
WO2011132051A3 (fr) Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10
PH12017500089B1 (en) Aldosterone synthase inhibitors
IN2012DN03846A (fr)
CY1119702T1 (el) Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
TN2013000483A1 (en) Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
EA201591023A1 (ru) Твердая форма производного дигидропиридооксазина
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
AR093608A1 (es) Forma solida de un derivado de dihidro-pirido-oxazina
MX2014002343A (es) Inhibidores de parp.